Ac Immune Stock Operating Margin

ACIU Stock

USD 2.68 0.02 0.74%

AC Immune fundamentals help investors to digest information that contributes to AC Immune's financial success or failures. It also enables traders to predict the movement of ACIU Stock. The fundamental analysis module provides a way to measure AC Immune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AC Immune stock.

		Last Reported	Projected for Next Year
	Operating Profit Margin	(3.62)	(3.80)

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

AC Immune Company Operating Margin Analysis

AC Immune's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Operating Margin

Operating Income

Revenue

100

More About Operating Margin | All Equity Analysis

Current AC Immune Operating Margin

0.29 %

Most of AC Immune's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AC Immune is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

ACIU Operating Margin Driver Correlations

Understanding the fundamental principles of building solid financial models for AC Immune is extremely important. It helps to project a fair market value of ACIU Stock properly, considering its historical fundamentals such as Operating Margin. Since AC Immune's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of AC Immune's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of AC Immune's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Debt	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		1.0	0.98	-0.47	0.06	-0.04	0.95	0.98	0.82	0.81	0.54	-0.8	0.91	0.88	0.73	0.51
Total Stockholder Equity	1.0		0.98	-0.46	0.07	-0.04	0.94	0.98	0.81	0.81	0.54	-0.81	0.9	0.87	0.73	0.5
Net Tangible Assets	0.98	0.98		-0.35	0.09	-0.04	0.9	1.0	0.72	0.72	0.59	-0.89	0.85	0.85	0.79	0.38
Retained Earnings	-0.47	-0.46	-0.35		0.1	-0.34	-0.55	-0.31	-0.84	-0.86	0.12	0.01	-0.66	-0.46	0.03	-0.96
Accounts Payable	0.06	0.07	0.09	0.1		0.0	-0.02	0.08	0.03	-0.13	-0.41	-0.26	-0.05	-0.23	-0.21	-0.05
Net Receivables	-0.04	-0.04	-0.04	-0.34	0.0		-0.05	-0.07	0.15	0.18	-0.17	0.14	0.03	-0.01	-0.19	0.32
Total Liab	0.95	0.94	0.9	-0.55	-0.02	-0.05		0.89	0.85	0.87	0.49	-0.67	0.9	0.9	0.71	0.61
Total Current Assets	0.98	0.98	1.0	-0.31	0.08	-0.07	0.89		0.68	0.7	0.6	-0.9	0.83	0.86	0.81	0.33
Common Stock	0.82	0.81	0.72	-0.84	0.03	0.15	0.85	0.68		0.93	0.19	-0.43	0.93	0.67	0.32	0.88
Property Plant Equipment	0.81	0.81	0.72	-0.86	-0.13	0.18	0.87	0.7	0.93		0.26	-0.39	0.86	0.82	0.44	0.87
Current Deferred Revenue	0.54	0.54	0.59	0.12	-0.41	-0.17	0.49	0.6	0.19	0.26		-0.51	0.35	0.65	0.78	-0.05
Net Debt	-0.8	-0.81	-0.89	0.01	-0.26	0.14	-0.67	-0.9	-0.43	-0.39	-0.51		-0.63	-0.59	-0.7	-0.03
Capital Surpluse	0.91	0.9	0.85	-0.66	-0.05	0.03	0.9	0.83	0.93	0.86	0.35	-0.63		0.76	0.55	0.66
Net Invested Capital	0.88	0.87	0.85	-0.46	-0.23	-0.01	0.9	0.86	0.67	0.82	0.65	-0.59	0.76		0.86	0.47
Net Working Capital	0.73	0.73	0.79	0.03	-0.21	-0.19	0.71	0.81	0.32	0.44	0.78	-0.7	0.55	0.86		0.0
Capital Stock	0.51	0.5	0.38	-0.96	-0.05	0.32	0.61	0.33	0.88	0.87	-0.05	-0.03	0.66	0.47	0.0

Click cells to compare fundamentals

A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.

Competition

Predict AC Immune

Operating Profit Margin Over Time

ACIU Pretax Profit Margin

Pretax Profit Margin

(3.85)

At this time, AC Immune's Pretax Profit Margin is comparatively stable compared to the past year.

Based on the recorded statements, AC Immune has an Operating Margin of 0.2852%. This is 100.81% lower than that of the Biotechnology sector and 100.25% lower than that of the Health Care industry. The operating margin for all United States stocks is 105.18% lower than that of the firm.

ACIU Operating Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AC Immune's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AC Immune could also be used in its relative valuation, which is a method of valuing AC Immune by comparing valuation metrics of similar companies.

AC Immune is currently under evaluation in operating margin category among its peers.

AC Immune Current Valuation Drivers

We derive many important indicators used in calculating different scores of AC Immune from analyzing AC Immune's financial statements. These drivers represent accounts that assess AC Immune's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of AC Immune's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	581.8M	329.2M	338.2M	157.5M	356.0M	603.7M
Enterprise Value	391.1M	170.5M	258.9M	128.7M	281.0M	498.1M

AC Immune ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, AC Immune's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to AC Immune's managers, analysts, and investors.

Environmental

Governance

Social

ACIU Fundamentals

	Return On Equity	-0.31
	Return On Asset	-0.12
	Profit Margin	(0.97) %
	Operating Margin	0.29 %
	Current Valuation	101.62 M
	Shares Outstanding	98.94 M
	Shares Owned By Insiders	21.68 %
	Shares Owned By Institutions	28.80 %
	Number Of Shares Shorted	1.02 M
	Price To Earning	(16.96) X
	Price To Book	1.89 X
	Price To Sales	6.69 X
	Revenue	14.8 M
	Gross Profit	(56.4 M)
	EBITDA	(51.83 M)
	Net Income	(54.23 M)
	Cash And Equivalents	154.15 M
	Cash Per Share	1.83 X
	Total Debt	3.5 M
	Debt To Equity	0.01 %
	Current Ratio	13.28 X
	Book Value Per Share	1.30 X
	Cash Flow From Operations	(60.41 M)
	Short Ratio	8.14 X
	Earnings Per Share	(0.45) X
	Target Price	10.02
	Number Of Employees	133
	Beta	1.28
	Market Capitalization	274.07 M
	Total Asset	182.81 M
	Retained Earnings	(316.2 M)
	Working Capital	111.58 M
	Current Asset	160 M
	Current Liabilities	11 M
	Net Asset	182.81 M

About AC Immune Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze AC Immune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AC Immune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AC Immune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for ACIU Stock Analysis

When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC